{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:16:34Z","timestamp":1760145394293,"version":"build-2065373602"},"reference-count":62,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases (NIAID)","award":["HHSN272201700041I","HHSN272201800001I","HHSN75N93019D00016"],"award-info":[{"award-number":["HHSN272201700041I","HHSN272201800001I","HHSN75N93019D00016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Adenovirus infections of immunocompromised patients can cause life-threatening disseminated disease. While there are presently no drugs specifically approved to treat these infections, there are several compounds that showed efficacy against adenovirus in preclinical studies. For any such compound, low toxicity is an essential requirement. As cumulative drug effects can accentuate pathology, especially in patients with other morbidities, it is important to limit antiviral exposure to what is absolutely necessary. This is achievable by monitoring the virus burden of the patients and administering antivirals to suppress virus replication to a non-pathogenic level. We modeled such a system using Syrian hamsters infected with a replication-competent adenovirus vector, in which luciferase expression is coupled to virus replication. We found that virus replication could be followed in vivo in the same animal by repeated measurement of luciferase expression. To test the utility of an interrupted treatment regimen, we used NPP-669 and valganciclovir, two antiviral compounds with high and moderate anti-adenoviral efficacy, respectively. We found that short-term treatment of adenovirus-infected hamsters at times of peak virus replication can prevent virus-associated pathology. Thus, we believe that this animal model can be used to model different treatment regimens for anti-adenoviral compounds.<\/jats:p>","DOI":"10.3390\/v16081200","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T06:17:44Z","timestamp":1721974664000},"page":"1200","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Monitoring of the Effects of Anti-Adenoviral Treatment Regimens in a Permissive In Vivo Model"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5010-3241","authenticated-orcid":false,"given":"Ann E.","family":"Tollefson","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Cline-Smith","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline F.","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoling","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn M.","family":"Reyna","sequence":"additional","affiliation":[{"name":"TSRL, Inc., Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5748-4750","authenticated-orcid":false,"given":"Elke","family":"Lipka","sequence":"additional","affiliation":[{"name":"TSRL, Inc., Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott H.","family":"James","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoly","family":"Toth","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"ref_1","first-page":"267","article-title":"Adenoviruses","volume":"Volume DNA Viruses","author":"Knipe","year":"2022","journal-title":"Fields Virology"},{"key":"ref_2","unstructured":"Group, H.A.W. (2024, May 31). Available online: http:\/\/hadvwg.gmu.edu\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0041-1733802","article-title":"Adenovirus: Epidemiology, Global Spread of Novel Types, and Approach to Treatment","volume":"42","author":"Lynch","year":"2021","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.15585\/mmwr.mm6712a6","article-title":"Notes from the Field: Fatalities Associated with Human Adenovirus Type 7 at a Substance Abuse Rehabilitation Facility\u2014New Jersey, 2017","volume":"67","author":"Rozwadowski","year":"2018","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_6","first-page":"2200483","article-title":"Hepatitis of unknown aetiology in children\u2014Epidemiological overview of cases reported in Europe, 1 January to 16 June 2022","volume":"27","author":"Vaughan","year":"2022","journal-title":"Eurosurveillance"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2242544","DOI":"10.1080\/21505594.2023.2242544","article-title":"Pathogenicity and virulence of human adenovirus F41: Possible links to severe hepatitis in children","volume":"14","author":"Grand","year":"2023","journal-title":"Virulence"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1056\/NEJMoa1405870","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. children","volume":"372","author":"Jain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11908-014-0416-y","article-title":"Adenovirus: Current epidemiology and emerging approaches to prevention and treatment","volume":"16","author":"Sandkovsky","year":"2014","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1002\/1873-3468.13576","article-title":"Adenovirus persistence, reactivation, and clinical management","volume":"593","author":"Lion","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tim.2016.02.007","article-title":"The Persistent Mystery of Adenovirus Persistence","volume":"24","author":"King","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/infdis\/jiy323","article-title":"Use of Whole-Genome Sequencing of Adenovirus in Immunocompromised Pediatric Patients to Identify Nosocomial Transmission and Mixed-Genotype Infection","volume":"218","author":"Houldcroft","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: A randomized placebo-controlled Phase II trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14740338.2019.1662787","article-title":"Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation","volume":"18","author":"Razonable","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: A key class of antiviral drugs","volume":"4","author":"Holy","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01925-18","DOI":"10.1128\/AAC.01925-18","article-title":"Cidofovir diphosphate inhibits adenovirus 5 DNA polymerase via both non-obligate chain termination and direct inhibition, and polymerase mutations confer cidofovir resistance on intact virus","volume":"63","author":"Chamberlain","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1124\/mol.56.3.570","article-title":"The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1","volume":"56","author":"Cihlar","year":"1999","journal-title":"Mol. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jpids\/pix011","article-title":"Renal Toxicity in Pediatric Patients Receiving Cidofovir for the Treatment of Adenovirus Infection","volume":"6","author":"Vora","year":"2017","journal-title":"J. Pediatric. Infect. Dis. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1586\/14787210.2014.948847","article-title":"Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses","volume":"12","author":"Florescu","year":"2014","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"Florescu","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.0800200105","article-title":"Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model","volume":"105","author":"Toth","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MPH.0000000000001227","article-title":"Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD","volume":"40","author":"Detweiler","year":"2018","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2217\/fmb-2019-0288","article-title":"Brincidofovir: Understanding its unique profile and potential role against adenovirus and other viral infections","volume":"15","author":"Whited","year":"2020","journal-title":"Future Microbiol."},{"key":"ref_27","unstructured":"(2024, June 27). FDA TEMBEXA (Brincidofovir) Tablets, for Oral Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214460s001,214461s001lbl.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e00284-17","DOI":"10.1128\/JVI.00284-17","article-title":"Pathology in permissive Syrian hamsters after infection with species C human adenovirus (HAdV-C) is the result of virus replication: HAdV-C6 replicates more and causes more pathology than HAdV-C5","volume":"91","author":"Tollefson","year":"2017","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"dmm044602","DOI":"10.1242\/dmm.044602","article-title":"Generation and characterization of an IL2RG knockout Syrian hamster model for XSCID and HAdV-C6 infection in immunocompromised patients","volume":"13","author":"Li","year":"2020","journal-title":"Dis. Models Mech."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Miao, J., Ying, B., Li, R., Tollefson, A.E., Spencer, J.F., Wold, W.S.M., Song, S.H., Kong, I.K., Toth, K., and Wang, Y. (2018). Characterization of an N-terminal non-core domain of RAG1 gene disrupted Syrian hamster model generated by CRISPR Cas9. Viruses, 10.","DOI":"10.3390\/v10050243"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Toth, K., Lee, S.R., Ying, B., Spencer, J.F., Tollefson, A.E., Sagartz, J.E., Kong, I.K., Wang, Z., and Wold, W.S. (2015). STAT2 knockout Syrian hamsters support enhanced replication and pathogenicity of human adenovirus, revealing an important role of type I interferon response in viral control. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005084"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.virol.2017.10.015","article-title":"Male Syrian hamsters are more susceptible to intravenous infection with species C human adenoviruses than are females","volume":"514","author":"Ying","year":"2018","journal-title":"Virology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.virol.2015.07.024","article-title":"Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters","volume":"485","author":"Ying","year":"2015","journal-title":"Virology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/acs.molpharmaceut.2c00668","article-title":"NPP-669, a Novel Broad-Spectrum Antiviral Therapeutic with Excellent Cellular Uptake, Antiviral Potency, Oral Bioavailability, Preclinical Efficacy, and a Promising Safety Margin","volume":"20","author":"Lipka","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105799","DOI":"10.1016\/j.antiviral.2024.105799","article-title":"Oral USC-093, a novel homoserinamide analogue of the tyrosinamide (S)-HPMPA prodrug USC-087 has decreased nephrotoxicity while maintaining antiviral efficacy against human adenovirus infection of Syrian hamsters","volume":"222","author":"Tollefson","year":"2024","journal-title":"Antiviral Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2014.10.005","article-title":"Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model","volume":"112","author":"Tollefson","year":"2014","journal-title":"Antiviral Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e01299-20","DOI":"10.1128\/AAC.01299-20","article-title":"Filociclovir Is a Potent In Vitro and In Vivo Inhibitor of Human Adenoviruses","volume":"64","author":"Toth","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.03.001","article-title":"USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses","volume":"153","author":"Toth","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Toth, K., Spencer, J.F., Ying, B., Tollefson, A.E., and Wold, W.S.M. (2017). HAdV-C6 is a more relevant challenge virus than HAdV-C5 for testing antiviral drugs with the immunosuppressed Syrian hamster model. Viruses, 9.","DOI":"10.3390\/v9060147"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2017.08.002","article-title":"Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds","volume":"146","author":"Toth","year":"2017","journal-title":"Antiviral Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/v7031409","article-title":"Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters","volume":"7","author":"Toth","year":"2015","journal-title":"Viruses"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.omtn.2017.07.002","article-title":"Anti-adenoviral artificial microRNAs expressed from AAV9 vectors inhibit human adenovirus infection in immunosuppressed Syrian hamsters","volume":"8","author":"Schaar","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.omtn.2023.05.016","article-title":"Lipid nanoparticle-encapsulated, chemically modified anti-adenoviral siRNAs inhibit hepatic adenovirus infection in immunosuppressed Syrian hamsters","volume":"32","author":"Geisler","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12830","DOI":"10.1021\/acs.jmedchem.0c01226","article-title":"Discovery of Novel Substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors","volume":"63","author":"Xu","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e0048924","DOI":"10.1128\/aac.00489-24","article-title":"NPP-669, a prodrug of cidofovir, is highly efficacious against human adenovirus infection in the permissive Syrian hamster model","volume":"68","author":"Tollefson","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/cgt.2013.49","article-title":"The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors","volume":"20","author":"Young","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/cgt.2013.50","article-title":"The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model","volume":"20","author":"Young","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/08830180490265556","article-title":"Functions and mechanisms of action of the adenovirus E3 proteins","volume":"23","author":"Lichtenstein","year":"2004","journal-title":"Int. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/viro.2002.1772","article-title":"Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus","volume":"305","author":"Doronin","year":"2003","journal-title":"Virology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/jvi.70.4.2296-2306.1996","article-title":"The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells","volume":"70","author":"Tollefson","year":"1996","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1252495","DOI":"10.3389\/fped.2023.1252495","article-title":"A quick algorithmic review on management of viral infectious diseases in pediatric solid organ transplant recipients","volume":"11","author":"Moghadamnia","year":"2023","journal-title":"Front Pediatr"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/00007890-199911150-00015","article-title":"Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients","volume":"68","author":"Humar","year":"1999","journal-title":"Transplantation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e13527","DOI":"10.1111\/ctr.13527","article-title":"Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Florescu","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e14173","DOI":"10.1111\/tid.14173","article-title":"Adenovirus infection in allogeneic hematopoietic cell transplantation","volume":"25","author":"Cesaro","year":"2023","journal-title":"Transpl. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lloyd, M.G., Yee, M.B., Flot, J.S., Liu, D., Geiler, B.W., Kinchington, P.R., and Moffat, J.F. (2022). Development of Robust Varicella Zoster Virus Luciferase Reporter Viruses for In Vivo Monitoring of Virus Growth and Its Antiviral Inhibition in Culture, Skin, and Humanized Mice. Viruses, 14.","DOI":"10.3390\/v14040826"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/TP.0000000000003988","article-title":"Adenovirus Infection and Transplantation","volume":"106","author":"Cathro","year":"2022","journal-title":"Transplantation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/hum.2009.028","article-title":"Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus","volume":"20","author":"Doronin","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1158\/0008-5472.CAN-08-0488","article-title":"Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus","volume":"68","author":"Shashkova","year":"2008","journal-title":"Cancer Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/8\/1200\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:24:00Z","timestamp":1760109840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/8\/1200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":62,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["v16081200"],"URL":"https:\/\/doi.org\/10.3390\/v16081200","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}